🇺🇸 FDA
Pipeline program

NoV GI.1/GII.4 Bivalent VLP Vaccine

LV03-104

Phase 1 mab completed

Quick answer

NoV GI.1/GII.4 Bivalent VLP Vaccine for Gastroenteritis is a Phase 1 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Gastroenteritis
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials